First U.S. presentation of clinical and imaging results from
Phase IIIb trial evaluating treatment with Orencia plus
Methotrexate (MTX) combination therapy in patients positive for
anti-citrullinated protein (anti-CCP) antibodies with early
moderate to severe rheumatoid arthritis (RA)
Real-world data highlighting meaningful patient-reported
outcomes and reinforcing the established safety data of
Orencia
Data identifying potential prognostic factors and predictive
biomarkers for Orencia response
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16
abstracts for Orencia were accepted for presentation at the 2014
annual meeting of the American College of Rheumatology (ACR) taking
place from November 14-19, 2014 in Boston, MA. This year’s data
reinforce the Company’s commitment to evaluating the use of Orencia
in early moderate to severe RA and the potential impact on the
course of the disease.
Key presentations include:
- Efficacy results from AVERT
(Assessing Very Early Rheumatoid
arthritis Treatment), a Phase IIIb trial comparing Orencia
in combination with methotrexate (MTX) to MTX alone in patients
positive for anti-CCP antibodies with early moderate to severe RA,
including MRI imaging outcomes.
- Patient-reported outcomes from AVERT
through 12 months of therapy with Orencia in combination with MTX,
Orencia alone or MTX alone, and up to 6 months after treatment
withdrawal in patients with early moderate to severe RA.
- Studies highlighting real-world Orencia
data reinforcing its established safety results.
- An oral presentation highlighting
exploratory results from a sub-study of the APPRAISE (Assess
the OMERACT-EULAR PDUS score for early signs of
improvement of synovitis in RA patients
treated with abatacept) trial that was designed to help
identify potential biomarkers to predict patient response to the
combination of Orencia + MTX in patients with moderate to severe
RA.
- Data from the ACTION
(Abatacept In routine clinical
practice) trial, a real-world prospective study, identifying
prognostic factors for long-term retention with Orencia including
CCP- and Rheumatoid Factor (RF)- positivity.
“Our exciting data this year underscore our continued commitment
to understanding the earlier stages of moderate to severe RA and
the potential impact on the course of disease,” said Douglas
Manion, M.D., head of Specialty Development, Bristol-Myers Squibb.
“The efficacy, safety and real world data we will present help
provide valuable insight into treatment response and outcomes in
patients with earlier RA.”
The complete list of Bristol-Myers Squibb presentations is
below. Abstracts can be accessed on the ACR website at:
http://www.acrabstracts.org
Title
Date/Time
Early Moderate to
Severe RA Efficacy Data: AVERT
Stringent Criteria for Low Disease Activity and Remission after 12
Poster Presentation Months of Treatment, and after Treatment
Withdrawal, with Abatacept November 18 Monotherapy, Abatacept with
Methotrexate or Methotrexate Alone in 8:30 a.m. – 4 p.m. Early
Rheumatoid Arthritis Sustained
Improvements in Magnetic Resonance Imaging Outcomes with Poster
Presentation Abatacept Following the Withdrawal of All Treatment in
Patients with November 17 Early Rheumatoid Arthritis
8:30 a.m. – 4 p.m. Patient-Reported Outcomes Following 12
Months of Therapy with Poster Presentation Abatacept (Plus
Methotrexate or as Monotherapy) or Methotrexate and November 18 Up
to 6 Months after Treatment Withdrawal in Patients with Early 8:30
a.m. – 4 p.m. Rheumatoid Arthritis
Predictors of Drug-free Remission Following Treatment with
Abatacept Poster Presentation (in Combination with Methotrexate or
as Monotherapy) in Early November 18 Rheumatoid Arthritis
8:30 a.m. – 4 p.m. The Impact on Anti-Citrullinated
Protein Antibody Isotypes and Epitope Poster Presentation Fine
Specificity in Patients with Early RA Treated with Abatacept and
November 17 Methotrexate 8:30 a.m. – 4 p.m.
Safety and
Real-World Data
Pregnancy Outcomes Following Exposure to Abatacept During Pregnancy
Oral Presentation November 17 2:30 p.m.
– 4 p.m. Identification of Tuberculosis in Rheumatoid Arthritis
Patients Poster Presentation Initiating Therapy with Biologic or
Non-Biologic Disease-Modifying November 16 Anti-Rheumatic Drugs
Using Health Insurance Claims Data 8:30 a.m. –
4 p.m. Healthcare Costs Associated with Serious Infections among
Biologic- Poster Presentation Naïve Rheumatoid Arthritis Patients
Initiating First-Line Biologic November 17 Treatment
8:30 a.m. – 4 p.m. Comparison of Patient Characteristics,
Healthcare Costs, and Biologic Poster Presentation
Persistence Between Patients with Rheumatoid Arthritis Initiating
November 16 First- or Second-Line Subcutaneous Abatacept,
Adalimumab, or 8:30 a.m. – 4 p.m. Etanercept Are
Patients With Rheumatoid Arthritis Initiating a TNF Biologic Poster
Presentation Comparable to Patients Initiating a Non TNF? November
18 8:30 a.m. – 4 p.m.
Potential
Prognostic Factors and Predictive Biomarkers
Protein Quantification Using Mass Spectrometry Methods to Predict
Oral Presentation Response to Abatacept and Methotrexate
Combination Therapy in November 18 Rheumatoid Arthritis.
4:30 p.m. – 6 p.m. Prognostic Factors for IV Abatacept Retention in
Patients Who Have Poster Presentation Received at Least One Prior
Biologic Agent: 2-Year Results from a November 18 Prospective,
International, Real-World Study 8:30 a.m. – 4 p.m. Does Body
Mass Index Impact Long-Term Retention with Abatacept in Poster
Presentation Patients With RA Who Have Received at Least One Prior
Biologic Agent? November 18 2-Year Results from a Real-World,
International, Prospective Study 8:30 a.m. – 4 p.m. Do
Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease
Poster Presentation Activity? Analyses from the First Prospective
International Phase November 16 IIIb Study of PDUS Response in
Abatacept-Treated Patients with 8:30 a.m. – 4 p.m. Rheumatoid
Arthritis (RA) Analysis of Gene Expression
Fluctuation with Abatacept Highlights the Poster Presentation
Involvement of the Proteasome Pathway As a Mechanism of Action of
November 17 Abatacept in Rheumatoid Arthritis 8:30 a.m. – 4
p.m. Gene Expression Analyses of Abatacept- and Adalimumab-Treated
Patients Poster Presentation from the AMPLE Trial November 17
8:30 a.m. – 4 p.m.
About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune
disease characterized by inflammation in the lining of joints (or
synovium), causing joint damage with chronic pain, stiffness, and
swelling. RA causes limited range of motion and decreased joint
function. The condition is more common in women than in men, who
account for 75% of patients diagnosed with RA.
About ORENCIA
Orencia SC and IV is indicated for reducing signs and symptoms,
inducing major clinical response, inhibiting the progression of
structural damage, and improving physical function in adult
patients with moderately to severely active rheumatoid arthritis.
Orencia may be used as monotherapy or concomitantly with
disease-modifying antirheumatic drugs (DMARDs) other than tumor
necrosis factor (TNF) antagonists.
Orencia IV is indicated for reducing signs and symptoms in
pediatric patients 6 years of age and older with moderately to
severely active polyarticular juvenile idiopathic arthritis.
Orencia IV may be used as monotherapy or concomitantly with
methotrexate (MTX). The safety and efficacy of Orencia SC has not
been studied in patients under 18 years of age.
Orencia should not be administered concomitantly with TNF
antagonists.
Orencia is not recommended for use concomitantly with other
biologic RA therapy, such as anakinra.
Orencia is intended for use under the guidance of a physician or
healthcare practitioner.
Indication/Usage and Important Safety Information for
ORENCIAIndication and Usage
Adult Rheumatoid Arthritis (RA): ORENCIA is indicated for
reducing signs and symptoms, inducing major clinical response,
inhibiting the progression of structural damage, and improving
physical function in adult patients with moderately to severely
active RA. ORENCIA may be used as monotherapy or concomitantly with
disease-modifying, anti-rheumatic drugs (DMARDs) other than tumor
necrosis factor (TNF) antagonists.
Important Limitations of Use: ORENCIA should not be
administered concomitantly with TNF antagonists, and is not
recommended for use concomitantly with other biologic RA therapy,
such as anakinra.
Important Safety Information
Concomitant Use with TNF Antagonists: Concurrent therapy
with ORENCIA and a biologic DMARD is not recommended. In controlled
clinical trials, adult patients receiving concomitant intravenous
ORENCIA and TNF antagonist therapy experienced more infections
(63%) and serious infections (4.4%) compared to patients treated
with only TNF antagonists (43% and 0.8%, respectively), without an
important enhancement of efficacy.
Hypersensitivity: Anaphylaxis or anaphylactoid reactions
can occur during or after an infusion and can be life-threatening.
In controlled, double-blind and open-label clinical trials,
anaphylaxis and anaphylactoid reactions were reported in <0.1%
of adult patients dosed with intravenous ORENCIA. Other reactions
potentially associated with drug hypersensitivity, such as
hypotension, urticaria, and dyspnea, that occurred within 24 hours
of ORENCIA infusion, were uncommon (<1% each). In postmarketing
experience, a case of fatal anaphylaxis following the first
infusion of ORENCIA was reported. Appropriate medical support
measures for treating hypersensitivity reactions should be
available for immediate use. If an anaphylactic or other serious
allergic reaction occurs, administration of ORENCIA should be
stopped immediately and permanently discontinued, with appropriate
therapy instituted.
Infections: Serious infections, including sepsis and
pneumonia, have been reported in patients receiving ORENCIA. Some
of these infections have been fatal. Many of the serious infections
have occurred in patients on concomitant immunosuppressive therapy
which in addition to their underlying disease, could further
predispose them to infection. Caution should be exercised in
patients with a history of infection or underlying conditions which
may predispose them to infections. Treatment with ORENCIA should be
discontinued if a patient develops a serious infection. Patients
should be screened for tuberculosis and viral hepatitis in
accordance with published guidelines, and if positive, treated
according to standard medical practice prior to therapy with
ORENCIA.
Immunizations: Live vaccines should not be given
concurrently with ORENCIA or within 3 months of its discontinuation
as it may blunt the effectiveness of some immunizations.
Use in Patients with Chronic Obstructive Pulmonary Disease
(COPD): Adult COPD patients treated with ORENCIA developed
adverse events more frequently than those treated with placebo (97%
vs 88%, respectively). Respiratory disorders occurred more
frequently in patients treated with ORENCIA compared to those on
placebo (43% vs 24%, respectively), including COPD exacerbations,
cough, rhonchi, and dyspnea. A greater percentage of patients
treated with ORENCIA developed a serious adverse event compared to
those on placebo (27% vs 6%), including COPD exacerbation [3 of 37
patients (8%)] and pneumonia [1 of 37 patients (3%)]. Use of
ORENCIA in patients with RA and COPD should be undertaken with
caution, and such patients monitored for worsening of their
respiratory status.
Blood Glucose Testing: ORENCIA for intravenous
administration contains maltose, which may result in falsely
elevated blood glucose readings on the day of infusion when using
blood glucose monitors with test strips utilizing glucose
dehydrogenase pyrroloquinolinequinone (GDH-PQQ). Consider using
monitors and advising patients to use monitors that do not react
with maltose, such as those based on glucose dehydrogenase nicotine
adenine dinucleotide (GDH-NAD), glucose oxidase or glucose
hexokinase test methods. ORENCIA for subcutaneous (SC)
administration does not contain maltose; therefore, patients do not
need to alter their glucose monitoring.
Pregnant and Nursing Mothers: ORENCIA should be used
during pregnancy only if clearly needed. The risk for development
of autoimmune diseases in humans exposed in utero to abatacept has
not been determined. Nursing mothers should be informed of the
risk/benefit of continued breast-feeding or discontinuation of the
drug. A pregnancy registry has been established to monitor fetal
outcomes. Healthcare professionals are encouraged to register
pregnant patients exposed to ORENCIA by calling 1-877-311-8972.
Most Serious Adverse Reactions: Serious infections (3%
ORENCIA vs 1.9% placebo) and malignancies (1.3% ORENCIA vs 1.1%
placebo).
Malignancies: The overall frequency of malignancies was
similar between adult patients treated with ORENCIA or placebo.
However, more cases of lung cancer were observed in patients
treated with ORENCIA (0.2%) than those on placebo (0%). A higher
rate of lymphoma was seen compared to the general population;
however, patients with RA, particularly those with highly active
disease, are at a higher risk for the development of lymphoma. The
potential role of ORENCIA in the development of malignancies in
humans is unknown.
Most Frequent Adverse Events (≥10%): Headache, upper
respiratory tract infection, nasopharyngitis, and nausea were the
most commonly reported adverse events in the adult RA clinical
studies.
Note concerning SC ORENCIA: The safety and efficacy of SC
ORENCIA has not been studied in patients under 18 years of age.
Please read the Patient Information in the Full US Prescribing
Information.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases.
For more information about Bristol-Myers Squibb, visit
http://www.bms.com , or follow us on Twitter at
http://twitter.com/bmsnews
Orencia is a registered trademark of Bristol-Myers Squibb
Company.
About Bristol-Myers Squibb Immunoscience
The immune system is the body’s natural defense against disease.
These processes come into play in almost every human disease. That
is why Bristol-Myers Squibb is focused on exploring ways to harness
the body’s own immune system to treat immune-related diseases with
high unmet medical needs, including RA – a chronic, systemic,
inflammatory autoimmune disorder that affects the joints.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2013 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
Bristol-Myers SquibbMedia:Chris Clark,
609-252-6269chris.clark@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024